Chronic activation of FXR-induced liver growth with tissue-specific targeting Cyclin D1

References

• Forman BM, Goode E, Chen J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995;81:687–693.
   PubMed Web of Science ®Google Scholar
• Seol W, Choi HS, Moore DD. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol Endocrinol. 1995;9:72–85.
   PubMed Web of Science ®Google Scholar
• Maloney PR, Parks DJ, Haffner CD, et al. Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem. 2000;43:2971–2974.
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45:3569–3572.
   PubMed Web of Science ®Google Scholar
• Flatt B, Martin R, Wang TL, et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem. 2009;52:904–907.
   PubMed Web of Science ®Google Scholar
• Laffitte BA, Kast HR, Nguyen CM, et al. Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem. 2000;275:10638–10647.
   PubMed Web of Science ®Google Scholar
• Sinal CJ, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102:731–744.
   PubMed Web of Science ®Google Scholar
• Lu TT, Makishima M, Repa JJ, et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell. 2000;6:507–515.
   PubMed Web of Science ®Google Scholar
• Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 2000;6:517–526.
   PubMed Web of Science ®Google Scholar
• Massafra V, Pellicciari R, Gioiello A, et al. Progress and challenges of selective Farnesoid X Receptor modulation. Pharmacol Ther. 2018;191:162-177.
   PubMed Web of Science ®Google Scholar
• Yanger K, Knigin D, Zong Y, et al. Adult hepatocytes are generated by self-duplication rather than stem cell differentiation. Cell Stem Cell. 2014;15:340–349.
   PubMed Web of Science ®Google Scholar
• Borude P, Edwards G, Walesky C, et al. Hepatocyte-specific deletion of farnesoid X receptor delays but does not inhibit liver regeneration after partial hepatectomy in mice. Hepatology. 2012;56:2344–2352.
   PubMed Web of Science ®Google Scholar
• Huang W, Ma K, Zhang J, et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science. 2006;312:233–236.
   PubMed Web of Science ®Google Scholar
• Chen WD, Wang YD, Zhang L, et al. Farnesoid X receptor alleviates age-related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription. Hepatology. 2010;51:953–962.
   PubMed Web of Science ®Google Scholar
• Merlen G, Ursic-Bedoya J, Jourdainne V, et al. Bile acids and their receptors during liver regeneration: “Dangerous protectors”. Mol Aspects Med. 2017;56:25–33.
   PubMed Web of Science ®Google Scholar
• Milona A, Owen BM, van Mil S, et al. The normal mechanisms of pregnancy-induced liver growth are not maintained in mice lacking the bile acid sensor Fxr. Am J Physiol Gastrointest Liver Physiol. 2010;298:G151–158.
   PubMed Web of Science ®Google Scholar
• Dai X, De Souza AT, Dai H, et al. PPARalpha siRNA-treated expression profiles uncover the causal sufficiency network for compound-induced liver hypertrophy. PLoS Comput Biol. 2007;3:e30.
   PubMed Web of Science ®Google Scholar
• Hall AP, Elcombe CR, Foster JR, et al. Liver hypertrophy: a review of adaptive (adverse and non-adverse) changes–conclusions from the 3rd international ESTP expert workshop. Toxicol Pathol. 2012;40:971–994.
   PubMed Web of Science ®Google Scholar
• Miyaoka Y, Ebato K, Kato H, et al. Hypertrophy and unconventional cell division of hepatocytes underlie liver regeneration. Curr Biol. 2012;22:1166–1175.
   PubMed Web of Science ®Google Scholar
• Verbeke L, Mannaerts I, Schierwagen R, et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep. 2016;6:33453.
   PubMed Web of Science ®Google Scholar
• Wu W, Zhu B, Peng X, et al. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochem Biophys Res Commun. 2014;443:68–73.
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang J, Liu Q, et al. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 2009;51:380–388.
   PubMed Web of Science ®Google Scholar
• Liu Y, Binz J, Numerick MJ, et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest. 2003;112:1678–1687.
   PubMed Web of Science ®Google Scholar
• Wu WB, Xu YY, Cheng WW, et al. Agonist of farnesoid X receptor protects against bile acid induced damage and oxidative stress in mouse placenta–a study on maternal cholestasis model. Placenta. 2015;36:545–551.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Clerici C, Antonelli E, et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther. 2005;313:604–612.
   PubMed Web of Science ®Google Scholar
• Zeng W, Liu Z, Liu X, et al. Distinct Transcriptional and Alternative Splicing Signatures of Decidual CD4(+) T Cells in Early Human Pregnancy. Front Immunol. 2017;8:682.
   PubMed Web of Science ®Google Scholar
• Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14:178–192.
   PubMed Web of Science ®Google Scholar
• Carpenter AE, Jones TR, Lamprecht MR, et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006;7:R100.
   PubMed Web of Science ®Google Scholar
• Ryu D, Oh KJ, Jo HY, et al. TORC2 regulates hepatic insulin signaling via a mammalian phosphatidic acid phosphatase, LIPIN1. Cell Metab. 2009;9:240–251.
   PubMed Web of Science ®Google Scholar
• Wu W, Wang Y, Xu Y, et al. Dysregulated activation of c-Src in gestational trophoblastic disease contributes to its aggressive progression. Placenta. 2014;35:824–830.
   PubMed Web of Science ®Google Scholar
• Tetzlaff MT, Curry JL, Ivan D, et al. Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma. Mod Pathol. 2013;26:1153–1160.
   PubMed Web of Science ®Google Scholar
• Xing X, Burgermeister E, Geisler F, et al. Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy. Hepatology. 2009;49:979–988.
   PubMed Web of Science ®Google Scholar
• Shlyueva D, Stampfel G, Stark A. Transcriptional enhancers: from properties to genome-wide predictions. Nat Rev Genet. 2014;15:272–286.
   PubMed Web of Science ®Google Scholar
• Rosenbloom KR, Sloan CA, Malladi VS, et al. ENCODE data in the UCSC Genome Browser: year 5 update. Nucleic Acids Res. 2013;41:D56–63.
   PubMed Web of Science ®Google Scholar
• Yue F, Cheng Y, Breschi A, et al. A comparative encyclopedia of DNA elements in the mouse genome. Nature. 2014;515:355–364.
   PubMed Web of Science ®Google Scholar
• Booth CAG, Barkas N, Neo WH, et al. Ezh2 and Runx1 mutations collaborate to initiate lympho-myeloid leukemia in early thymic progenitors. Cancer Cell. 2018;33(274–291):e278.
   Google Scholar
• Lasko LM, Jakob CG, Edalji RP, et al. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature. 2017;550:128–132.
   PubMed Web of Science ®Google Scholar
• Thomas AM, Hart SN, Kong B, et al. Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. Hepatology. 2010;51:1410–1419.
   PubMed Web of Science ®Google Scholar
• Dawson PA, Hubbert M, Haywood J, et al. The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter. J Biol Chem. 2005;280:6960–6968.
   PubMed Web of Science ®Google Scholar
• Kong B, Wang L, Chiang JY, et al. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology. 2012;56:1034–1043.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Li F, Guo GL. Tissue-specific function of farnesoid X receptor in liver and intestine. Pharmacol Res. 2011;63:259–265.
   PubMed Web of Science ®Google Scholar
• Russo M, Natoli G, Ghisletti S. Housekeeping and tissue-specific cis-regulatory elements: recipes for specificity and recipes for activity. Transcription. 2018;9:177–181.
   PubMed Web of Science ®Google Scholar
• You W, Chen B, Liu X, et al. Farnesoid X receptor, a novel proto-oncogene in non-small cell lung cancer, promotes tumor growth via directly transactivating CCND1. Sci Rep. 2017;7:591.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu P, Park K, et al. Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. Hepatology. 2008;48:289–298.
   PubMed Web of Science ®Google Scholar
• Ohno T, Shirakami Y, Shimizu M, et al. Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand. Cancer Lett. 2012;323:215–222.
   PubMed Web of Science ®Google Scholar
• Kong B, Zhu Y, Li G, et al. Mice with hepatocyte-specific FXR deficiency are resistant to spontaneous but susceptible to cholic acid-induced hepatocarcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2016;310:G295–302.
   PubMed Web of Science ®Google Scholar
• Kim I, Morimura K, Shah Y, et al. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis. 2007;28:940–946.
   PubMed Web of Science ®Google Scholar
• Yang F, Huang X, Yi T, et al. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007;67:863–867.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Inaba Y, Lu P, et al. Chronic activation of FXR in transgenic mice caused perinatal toxicity and sensitized mice to cholesterol toxicity. Mol Endocrinol. 2015;29:571–582.
   PubMedGoogle Scholar